Explore more
News
Novo Nordisk ousts CEO
Digest more
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...
3don MSN
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects. The ...
Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A ...
Most major stock indexes across the globe moved upwards on a weekly basis, taking support from the uptick in US equities.
Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback